ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter

Takeda expects to launch a better dengue vaccine

Japanese pharmaceutical sees the neutralizer benefiting young children

Rajeev Venkayya, president of Takeda Pharmaceutical’s global vaccine business

TOKYO -- Nearly 400,000 people come down with dengue fever every year. The mosquito-borne tropical disease appears especially fond of Asia, which accounts for 70% of the infections. While France's Sanofi licensed the first dengue vaccine in 2015, the counteractant has been ineffective for young children. 

Rajeev Venkayya, president of Takeda Pharmaceutical's global vaccine business, expects a new neutralizer to fill the gap in Asia.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more